BiotechTube
CasZyme

CasZyme

Vilnius, Europe - Other· Est.
caszyme.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CasZyme is a privately held CRISPR technology company based in Vilnius, Lithuania, founded by pioneering scientists in the field. The company combines its proprietary nuclease discovery and engineering platform with extensive expertise to provide customized CRISPR solutions across therapeutics, agriculture, diagnostics, research tools, and industrial biotechnology. Its core asset is the novel Cas12l nuclease platform, and it operates primarily as a B2B platform and services provider, partnering with other companies to advance their CRISPR-based applications.

CRISPRGenetics & Genomics

Technology Platform

Proprietary CRISPR nuclease discovery and engineering platform, featuring the novel Cas12l nuclease (~850 aa, CCY PAM) and expertise in mRNA, protein evolution, and custom CRISPR solution development.

Opportunities

The expansive growth of CRISPR applications across therapeutics, agriculture, diagnostics, and industrial biotech creates a large addressable market for a specialized tools and services provider.
CasZyme's novel Cas12l nuclease, with its small size and unique properties, addresses key delivery and targeting challenges, presenting a significant licensing opportunity.
Its position in Europe allows it to capitalize on the region's growing biotech ecosystem and funding initiatives.

Risk Factors

Intense competition from larger, well-funded CRISPR companies and platforms developing similar compact nucleases threatens CasZyme's market position.
Its B2B partnership model creates revenue dependency on the success and priorities of its clients, leading to potential volatility.
Navigating the complex and contested global CRISPR intellectual property landscape remains a persistent legal and financial challenge.

Competitive Landscape

CasZyme competes in the crowded CRISPR tools and services sector against large public companies (e.g., CRISPR Therapeutics, Intellia, Editas Medicine), major life science tools vendors (e.g., Thermo Fisher, GenScript), and other niche platform companies. Its differentiation hinges on its proprietary Cas12l nuclease, deep academic roots in CRISPR pioneer research, and its flexible, partnership-driven approach to solving specific client challenges across diverse sectors.

More companies in Europe - Other →